Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy

Diabetes

Volumn 54, Issue 5, 2005, Pages 1514-1522

  Li, Fei ^a   Drel, Viktor R ^b   Szabó, Csaba ^c   Stevens, Martin J ^a   Obrosova, Irina G ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c INOTEK CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ISOQUINOLINEDIOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; SALBUTAMOL; STREPTOZOCIN; UNCLASSIFIED DRUG; VASODILATOR AGENT;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DIABETIC NEUROPATHY; DNA REPAIR; ENDOTHELIUM CELL; ENZYME INHIBITION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HYPERALGESIA; IN VITRO STUDY; LONG TERM CARE; LOW DRUG DOSE; MALE; MOTOR NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHWANN CELL; SCIATIC NERVE; SENSORY NERVE; SIDE EFFECT; WESTERN BLOTTING;

ALBUTEROL; ANIMALS; CELLS, CULTURED; DIABETIC NEUROPATHIES; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; LISINOPRIL; MALE; MOTOR NEURONS; NEURAL CONDUCTION; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, WISTAR; REGIONAL BLOOD FLOW; SCHWANN CELLS;

EID: 17844367634     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.5.1514     Document Type: Article

References (50)

1. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabo C: Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7:108-113, 2001
2. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M: Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049-1057, 2003
3. Obrosova IG, Li F, Abatan OI, Forsell MA, Komjati K, Pacher P, Szabo C, Stevens MJ: Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53:711-720, 2004
4. Zheng L, Szabo C, Kern TS: Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 53:2960-2967, 2004
5. Virag L, Szabo C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54:375-429, 2002
6. Ha HC, Hester LD, Snyder SH: Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci U S A 99:3270-3275, 2002
7. Minchenko AG, Stevens MJ, White L, Abatan OI, Komjati K, Pacher P, Szabo C, Obrosova IG: Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 17:1514-1516, 2003
8. Li F, Szabo C, Pacher P, Southan GJ, Abatan OI, Charniauskaya T, Stevens MJ, Obrosova IG: Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 47:710-717, 2004
9. Karasu C, Dewhurst M, Stevens EJ, Tomlinson DR: Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats: comparison with essential fatty acids. Diabetologia 38:129-134, 1995
10. Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA: Effects of DL-α-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49:1006-1015, 2000
11. Schmeichel AM, Schmelzer JD, Low PA: Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52:165-171, 2003
12. Ullrich O, Diestel A, Eyupoglu IY, Nitsch R: Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol 3:1035-1042, 2001
13. Kameoka M, Nukuzuma S, Itaya A, Tanaka Y, Ota K, Ikuta K, Yoshihara K: RNA interference directed against poly(ADP-ribose) polymerase 1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells. J Virol 78:8931-8934, 2004
14. Cotter MA, Mirrlees DJ, Cameron NE: Neurovascular interactions between aldose reductase and angiotensin-converting enzyme inhibition in diabetic rats. Eur J Pharmacol 417:223-230, 2001
15. 1- adrenoceptor antagonist treatment interactions with the nitric oxide system. Eur J Pharmacol 343:217-223, 1998
16. Reja A, Tesfaye S, Harris ND, Ward JD: Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabet Med 12:307-309, 1995
17. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. Biotechnology 24:145-149, 1992
18. Thornalley PJ: Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 50:37-57, 2002
19. Calcutt NA, Freshwater JD, Mizisin AP: Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 47:718-724, 2004
20. Greene DA, Arezzo JC, Brown MB: Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy: Zenarestat Study Group. Neurology 53:580-591, 1999
21. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N, SNK-860 Diabetic Neuropathy Study Group: Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multi-center placebo-controlled double-blind parallel group study. Diabetes Care 24:1776-1782, 2001
22. Wada R, Nishizawa Y, Yagihashi N, Takeuchi M, Ishikawa Y, Yasumura K, Nakano M, Yagihashi S: Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 31:513-520, 2001
23. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM: Diabetic somatic neuropathies. Diabetes Care 27:1458-1486, 2004
24. Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, Nakashima E, Naruse K, Kasuya Y, Mizubayashi R, Miwa K, Yasuda Y, Kamiya H, Ienaga K, Sakakibara F, Koh N, Hotta N: A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48:2090-2095, 1999
25. Hounsom L, Corder R, Patel J, Tomlinson DR: Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy. Diabetologia 44:424-428, 2001
26. Mizisin AP, Vu Y, Shuff M, Calcutt NA: Ciliary neurotrophic factor improves nerve conduction and ameliorates regeneration deficits in diabetic rats. Diabetes 53:1807-1812, 2004
27. Obrosova IG, Mabley JG, Zsengeller Z, Charniauskaya T, Abatan OI, Groves JT, Szabo C: Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J 19:401-403, 2005
28. Price SA, Agthong S, Middlemas AB, Tomlinson DR: Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase. Diabetes 53:1851-1856, 2004
29. Li F, Obrosova IG, Abatan O, Tian D, Larkin D, Stuenkel EL, Stevens MJ: Taurine replacement attenuates hyperalgesia and abnormal calcium signaling in sensory neurons of streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab 288:E29-E36, 2005
30. Boulton AJ: Treatments for diabetic neuropathy. Curr Diab Rep 1:127-132, 2001
31. Hounsom L, Horrobin DF, Tritschler H, Corder R, Tomlinson DR: A lipoic acid-γ linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia 41:839-843, 1998
32. Cameron NE, Cotter MA: Effects of protein kinase C β inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev 18:315-323, 2002
33. Cameron NE, Cotter MA: Effects of a nonpeptide endothelin-1 ETA antagonist on neurovascular function in diabetic rats: interaction with the renin-angiotensin system. J Pharmacol Exp Ther 278:1262-1268, 1996
34. Yorek MA, Coppey LJ, Gellett JS, Davidson EP, Lund DD: Effect of fidarestat and α-lipoic acid on diabetes-induced epineurial arteriole vascular dysfunction. Exp Diabesity Res 5:123-135, 2004
35. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
36. Yorek MA: The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res 37:471-480, 2003
37. Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, Veves A: Poly(ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106:2680-2686, 2002
38. Obrosova IG, Minchenko AG, Frank RN, Seigel GM, Zsengeller Z, Pacher P, Stevens MJ, Szabo C: Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int J Mol Med 14:55-64, 2004
39. Cheng C, Zochodne DW: Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 52:2363-2371, 2003
40. Noda Y, Mori A, Packer L: Free radical scavenging properties of alacepril metabolites and lisinopril. Res Commun Mol Pathol Pharmacol 96:125-136, 1997
41. 2-Adrenergic receptor stimulation-induced immunosuppressive effects possibly through down-regulation of co-stimulatory molecules, ICAM-1, CD40 and CD14 on monocytes. J Int Med Res 32:465-483, 2004
42. Meliton AY, Munoz NM, Liu J, Lambertino AT, Boetticher E, Myo S, Myou S, Zhu X, Johnson M, Leff AR: Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: effect of salmeterol and PDE4 inhibition in human eosinophils. J Allergy Clin Immunol 112:404-410, 2003
43. 2+ channel Cav1.2, Science 293:98-101, 2001
44. Zimmer HG, Ibel H, Suchner U: β-Adrenergic agonists stimulate the oxidative pentose phosphate pathway in the rat heart. Circ Res 67:1525-1534, 1990
45. Calcutt NA: Potential mechanisms of neuropathic pain in diabetes, Int, Rev Neurobiol 50:205-228, 2002
46. Cameron N, Cotter M, Inkster M, Nangle M: Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diabetes Res Clin Pract 61(Suppl. 1):S35-S39, 2003
47. Cotter MA, Jack AM, Cameron NE: Effects of the protein kinase C β inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci 103:311-321, 2002
48. Cameron NE, Jack AM, Cotter MA: Effect of α-lipoic acid on vascular responses and nociception in diabetic rats, free Radic Biol Med 31:125-135, 2001
49. Cameron NE, Tuck Z, McCabe L, Cotter MA: Effect of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes. Diabetologia 44:1161-1169, 2001
50. Calcutt NA, Allendoerfer KL, Mizisin AP, Middlemas A, Freshwater JD, Burgers M, Ranciato R, Delcroix JD, Taylor FR, Shapiro R, Strauch K, Dudek H, Engber TM, Galdes A, Rubin LL, Tomlinson DR: Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy. J Clin Invest 111:507-514, 2003